{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T20:46:31Z","timestamp":1775162791897,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T00:00:00Z","timestamp":1662249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100016288","name":"Kissei","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016288","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["LUTS"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Pharmacological treatment options for underactive bladder (UAB) syndrome are limited. Urapidil is the only alpha<jats:sub>1<\/jats:sub>\u2010adrenoceptor (AR) antagonist that can be used for urinary disorders in women in some countries. However, no studies have directly verified the effects of alpha<jats:sub>1<\/jats:sub>\u2010AR antagonists on the female urethra and UAB\u2010like dysfunctions. We investigated the effects of silodosin (alpha<jats:sub>1A<\/jats:sub>\u2010AR antagonist) and urapidil (nonselective alpha<jats:sub>1<\/jats:sub>\u2010AR antagonist) on the voiding function in female rats with diabetes mellitus (DM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Changes in intraurethral pressure (IUP) induced by midodrine (alpha<jats:sub>1<\/jats:sub>\u2010AR agonist) and mean blood pressure (MBP) were continuously measured in normal female rats to verify the pharmacological profiles of the drugs. To establish a DM model, rats were administered streptozotocin (STZ; 50\u2009mg\/kg, intravenous). Eight weeks after STZ administration, drugs were subcutaneously delivered through an osmotic pump. Four weeks after drug administration, emptied bladder blood flow (BBF), intravesical pressure, and the micturition volume were measured.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Both silodosin and urapidil inhibited the midodrine\u2010induced increase in IUP and decreased MBP in a dose\u2010dependent manner. Silodosin had a more substantial effect on the lower urinary tract than on MBP. Twelve weeks after STZ administration, DM rats exhibited UAB\u2010like dysfunction (increased bladder capacity\/bladder weight and residual volume and decreased bladder voided efficiency) and decreased BBF. Both drug treatments controlled this dysfunction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Alpha<jats:sub>1<\/jats:sub>\u2010AR antagonists induced dose\u2010dependent urethral relaxation in female rats. These drugs ameliorated UAB\u2010like dysfunction in STZ\u2010induced DM rats. In addition, alpha<jats:sub>1A<\/jats:sub>\u2010AR antagonists such as silodosin, which have limited effects on blood pressure, appear to be useful for treating UAB.<\/jats:p><\/jats:sec>","DOI":"10.1111\/luts.12462","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T06:38:34Z","timestamp":1662359914000},"page":"434-441","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic effects of silodosin and urapidil on underactive bladder associated with diabetic cystopathy"],"prefix":"10.1111","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0577-0058","authenticated-orcid":false,"given":"Saori","family":"Yonekubo\u2010Awaka","sequence":"first","affiliation":[{"name":"Central Research Laboratories Kissei Pharmaceutical Co, Ltd  Matsumoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiro","family":"Tezuka","sequence":"additional","affiliation":[{"name":"Central Research Laboratories Kissei Pharmaceutical Co, Ltd  Matsumoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Tatemichi","sequence":"additional","affiliation":[{"name":"Central Research Laboratories Kissei Pharmaceutical Co, Ltd  Matsumoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroo","family":"Takeda","sequence":"additional","affiliation":[{"name":"Central Research Laboratories Kissei Pharmaceutical Co, Ltd  Matsumoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,9,4]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.10.015"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23701"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.005"},{"issue":"1","key":"e_1_2_11_5_1","first-page":"127","article-title":"The effectiveness of parasympathomimetics for treating underactive bladder: a systematic review and meta\u2010analysis","volume":"41","author":"Christian M","year":"2022","journal-title":"NeurourolUrodyn"},{"issue":"2","key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1742-1241.1994.tb09770.x","article-title":"Cholinergic crisis following treatment of postoperative urinary retention with distigmine bromide","volume":"48","author":"Hameed A","year":"1994","journal-title":"Br J Clin Pract"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000019818"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(94)90141-4"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856050-00016"},{"key":"e_1_2_11_10_1","first-page":"81","article-title":"KMD\u20103213, a uroselective and long\u2010acting alpha(1a)\u2010adrenoceptor antagonist, tested in a novel rat model","volume":"291","author":"Akiyama K","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000000381"},{"issue":"1","key":"e_1_2_11_12_1","first-page":"11","article-title":"The other bladder syndrome: underactive bladder","volume":"15","author":"Miyazato M","year":"2013","journal-title":"Rev Urol"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-014-0808-9"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.4111\/icu.2017.58.S2.S82"},{"issue":"60","key":"e_1_2_11_15_1","first-page":"S8","article-title":"Animal models of diabetic uropathy","volume":"182","author":"Daneshgari F","year":"2009","journal-title":"J Urol"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-017-0256-9"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.2004.03950.x"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701731"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.06.042"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2014.03.002"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64636-8"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-014-0778-y"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(06)00582-9"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14121"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCMA.0000000000000593"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2004.00753.x"}],"container-title":["LUTS: Lower Urinary Tract Symptoms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/luts.12462","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/luts.12462","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/luts.12462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T22:00:03Z","timestamp":1692655203000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/luts.12462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,4]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1111\/luts.12462"],"URL":"https:\/\/doi.org\/10.1111\/luts.12462","archive":["Portico"],"relation":{},"ISSN":["1757-5664","1757-5672"],"issn-type":[{"value":"1757-5664","type":"print"},{"value":"1757-5672","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,4]]},"assertion":[{"value":"2022-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}